NCT07193316View on ClinicalTrials.gov

Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis

Active, not recruitingOBSERVATIONAL
Enrollment

741

Participants

Timeline

Start Date

July 27, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions
Hepatocellular CarcinomaLiver Cirrhosis
Interventions
OTHER

no intervention

no intervention

Trial Locations (1)

00168

Fondazione Policlinico Agostino Gemelli IRCCS, Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER